Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

10/01/2023

B2RLaw advises Polish unicorn DocPlanner on its acquisition of MyDr

B2RLaw has advised Polish unicorn DocPlanner on its acquisition of MyDr – DocPlanner’s first acquisition on the Polish market. Docplanner […]

MORE
02/01/2023

New Compliance 360 practice at B2RLaw

B2RLaw has established a multidisciplinary team whose aim is to support clients in monitoring and adapting their activities to the […]

MORE
28/11/2022

B2RLaw advises on the sale of award-winning Gdynia office complex

B2RLaw has advised the sellers (a Dutch company and Polish companies) on the sale of Łużycka Office Park (buildings A, […]

MORE
15/11/2022

B2RLaw advises SaaS-enabled B2B marketplace for the healthcare industry, Dentametr, on a pre-seed round with investors, which includes Octopus Ventures

B2RLaw has advised Dentametr and its founders on its pre-seed round capital raise with investors including leading investment fund Octopus […]

MORE
08/11/2022

B2RLaw advises Auxilius Pharma on capital raise to fuel groundbreaking growth to the US market

B2RLaw advised Auxilius Pharma Sp. z o.o. and its founders on a venture capital transaction related to the investment of […]

MORE
03/11/2022

B2RLaw advises Westcoast on merger to create EUR 5.5 billion ICT distributor

B2RLaw has advised the UK’s largest privately owned information and communications technology company Westcoast on Polish aspects of its merger […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close